Phreesia's Network Solutions Business Attracts Mizuho's Outperform Rating
PorAinvest
miércoles, 27 de agosto de 2025, 2:20 pm ET1 min de lectura
PHR--
Valiquette underscores that the network solutions business has been a key driver for Phreesia's EBITDA margins, which have improved to +18-19% in 2025. He expects further enhancements in the company's EBITDA margins, with a potential +15-20% compound annual growth rate (CAGR) in network solutions revenue. The analyst has set a $36 per share target on the stock, noting that Phreesia currently trades at a nearly 14x enterprise value (EV)/EBITDA multiple for 2026 estimates, compared to an average multiple of ~17x among its healthcare tech peers.
The Mizuho analyst's recommendation underscores the growing demand for patient engagement solutions and Phreesia's ability to leverage its network solutions business to drive revenue acceleration. Investors should closely monitor Phreesia's financial performance and the continued growth prospects of its network solutions business.
References:
[1] https://seekingalpha.com/news/4489705-phreesia-stock-new-outperform-mizuho
Phreesia, a patient intake management software developer, has seen its stock rise after Mizuho launched coverage with an Outperform recommendation. The recommendation is based on potential in the company's network solutions business, which generated $121.6M in revenue for 2022. Mizuho expects Phreesia's network solutions business to continue to grow, driven by increasing demand for patient engagement solutions.
Phreesia (NYSE: PHR), a developer of patient intake management software, experienced a significant stock rise following Mizuho's launch of its coverage with an Outperform recommendation. The recommendation is centered on the company's network solutions business, which generated $121.6 million in revenue for 2022 [1]. Mizuho analyst Steven Valiquette highlighted the potential of this business, which provides patients with customized health content and allows Phreesia to capitalize on pharma digital marketing expenditure. The network solutions business has demonstrated robust growth, with revenue increasing by ~29% year-over-year (YoY) in 2025 compared to ~27% YoY growth in 2024.Valiquette underscores that the network solutions business has been a key driver for Phreesia's EBITDA margins, which have improved to +18-19% in 2025. He expects further enhancements in the company's EBITDA margins, with a potential +15-20% compound annual growth rate (CAGR) in network solutions revenue. The analyst has set a $36 per share target on the stock, noting that Phreesia currently trades at a nearly 14x enterprise value (EV)/EBITDA multiple for 2026 estimates, compared to an average multiple of ~17x among its healthcare tech peers.
The Mizuho analyst's recommendation underscores the growing demand for patient engagement solutions and Phreesia's ability to leverage its network solutions business to drive revenue acceleration. Investors should closely monitor Phreesia's financial performance and the continued growth prospects of its network solutions business.
References:
[1] https://seekingalpha.com/news/4489705-phreesia-stock-new-outperform-mizuho

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios